Trade Desk to replace Ansys in the S&P 500
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.73% at $464.20. The stock trailed the S&P 500, which registered a daily loss of 0.4%. At the same time, the Dow lost 0.98%, and the tech-heavy Nasdaq gained 0.18%. Coming into today, shares of the drugmaker had gained 4.75% in the past month. In that same time, the Medical sector lost 1.56%, while the S&P 500 gained 4.97%. Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company plans to announce its earnings on August 4, 2025. In that report, analysts expect Vertex Pharmaceuticals to post earnings of $4.25 per share. This would mark year-over-year growth of 133.13%. Alongside, our most recent consensus estimate is anticipating revenue of $2.89 billion, indicating a 9.11% upward movement from the same quarter last year. For the full year, the Zacks Consensus Estimates are projecting earnings of $17.83 per share and revenue of $11.91 billion, which would represent changes of +4145.24% and +8.07%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for Vertex Pharmaceuticals. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.08% higher. As of now, Vertex Pharmaceuticals holds a Zacks Rank of #3 (Hold). Looking at valuation, Vertex Pharmaceuticals is presently trading at a Forward P/E ratio of 26.5. For comparison, its industry has an average Forward P/E of 17.7, which means Vertex Pharmaceuticals is trading at a premium to the group. The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 77, finds itself in the top 32% echelons of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
an hour ago
- Yahoo
Ulta Beauty (ULTA) Dips More Than Broader Market: What You Should Know
In the latest trading session, Ulta Beauty (ULTA) closed at $473.78, marking a -1.23% move from the previous day. This change lagged the S&P 500's 0.4% loss on the day. Meanwhile, the Dow lost 0.98%, and the Nasdaq, a tech-heavy index, added 0.18%. The beauty products retailer's stock has climbed by 1.64% in the past month, falling short of the Retail-Wholesale sector's gain of 4.14% and the S&P 500's gain of 4.97%. The upcoming earnings release of Ulta Beauty will be of great interest to investors. It is anticipated that the company will report an EPS of $4.87, marking a 8.11% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $2.6 billion, reflecting a 1.7% rise from the equivalent quarter last year. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $23.39 per share and a revenue of $11.64 billion, indicating changes of -7.7% and +3.04%, respectively, from the former year. Investors should also take note of any recent adjustments to analyst estimates for Ulta Beauty. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.65% fall in the Zacks Consensus EPS estimate. Ulta Beauty is currently sporting a Zacks Rank of #3 (Hold). In terms of valuation, Ulta Beauty is currently trading at a Forward P/E ratio of 20.51. This signifies a premium in comparison to the average Forward P/E of 13.56 for its industry. Investors should also note that ULTA has a PEG ratio of 2.91 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Retail - Miscellaneous industry had an average PEG ratio of 2.91. The Retail - Miscellaneous industry is part of the Retail-Wholesale sector. This industry, currently bearing a Zacks Industry Rank of 178, finds itself in the bottom 28% echelons of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ulta Beauty Inc. (ULTA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Riot Platforms, Inc. (RIOT) Falls More Steeply Than Broader Market: What Investors Need to Know
Riot Platforms, Inc. (RIOT) ended the recent trading session at $12.10, demonstrating a -3.28% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.4%. Elsewhere, the Dow saw a downswing of 0.98%, while the tech-heavy Nasdaq appreciated by 0.18%. Shares of the company have appreciated by 23.01% over the course of the past month, outperforming the Finance sector's gain of 4.41%, and the S&P 500's gain of 4.97%. Market participants will be closely following the financial results of Riot Platforms, Inc. in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.19, reflecting a 40.63% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $149.8 million, reflecting a 113.94% rise from the equivalent quarter last year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.44 per share and revenue of $643.37 million, indicating changes of -523.53% and +70.81%, respectively, compared to the previous year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Riot Platforms, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.37% higher within the past month. Riot Platforms, Inc. presently features a Zacks Rank of #3 (Hold). The Financial - Miscellaneous Services industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 85, which puts it in the top 35% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Riot Platforms, Inc. (RIOT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
